Active substanceInosineInosine
Similar drugsTo uncover
  • Inosie-F®
    solution in / in 
    Europharm (UK) Co., Ltd.     United Kingdom
  • Inosine
    solution in / in 
    Ama Pharm, OOO     China
  • Inozin-Eskom
    solution in / in 
    ESKOM NPK, OAO     Russia
  • Riboxin
    solution in / in 
    ATOLL, LLC     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    IRBITSK HFZ, OJSC     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    solution in / in 
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    MAKSFARM, OJSC     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    BINNOFARM, CJSC     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    OZONE, LLC     Russia
  • Riboxin
    pills inwards 
    BIOSINTEZ, PAO     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    DALHIMFARM, OJSC     Russia
  • Riboxin
    solution in / in 
    BIOSINTEZ, PAO     Russia
  • Riboxin
    pills inwards 
    NORTH STAR, CJSC     Russia
  • Riboxin
    capsules inwards 
    MINSKINTERKAPS, UP     Republic of Belarus
  • Riboxin
    solution in / in 
    VEROPHARM SA     Russia
  • Riboxin
    pills inwards 
    Mapichem AG     Switzerland
  • Riboxin
    solution in / in 
    Mapichem AG     Switzerland
  • Riboxin
    solution in / in 
    DALHIMFARM, OJSC     Russia
  • Riboxin
    solution in / in 
    ELLARA, LTD.     Russia
  • Riboxin
    solution in / in 
    GROTEKS, LLC     Russia
  • Riboxin
    solution in / in 
    VELFARM, LLC     Republic of San Marino
  • Riboxin of Avexime
    pills inwards 
  • Riboxin Beefus
    solution in / in 
    UPDATE OF PFC, CJSC     Russia
  • Riboxin-Vial
    solution in / in 
    VIAL, LLC     Russia
  • Riboxin-LexT
    pills inwards 
  • Riboxin-Ferein
    pills inwards 
    BRYNTSALOV-A, CJSC     Russia
  • ASFARMA, LLC     Russia
  • Dosage form: & nbspsolution for intravenous administration
    Composition:

    1 ml of the solution contains:

    active substance: riboxin (inosine) 20 mg;

    Excipients: sodium hydroxide 4.8 mg, hydrochloric acid diluted to pH 8.5 to 9.5, sodium chloride 8.5 mg, water for injection q.s. up to 1 ml.

    Description:Transparent colorless or slightly colored liquid.
    Pharmacotherapeutic group:metabolic
    ATX: & nbsp

    C.01.E.B   Other drugs for the treatment of heart disease

    Pharmacodynamics:

    Riboxin is a derivative (nucleoside) of purine, a precursor of adenosine triphosphate (ATP). Refers to a group of drugs that stimulate metabolic processes. Has antihypoxic and antiarrhythmic effect. Increases the energy balance of the myocardium, improves coronary circulation, prevents the consequences of intraoperative kidney ischemia. It takes a direct part in the exchange of glucose and promotes the activation of metabolism in conditions of hypoxia and in the absence of ATP. Activates the metabolism of pyruvic acid to ensure a normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase. Stimulates the synthesis of nucleotides, enhances the activity of certain enzymes of the Krebs cycle. Penetrating into cells, it has a positive effect on the metabolic processes in the myocardium - it increases the strength of the heart contractions and promotes more complete relaxation of the myocardium in diastole, as a result of which the stroke volume increases. The mechanism of antiarrhythmic action is not fully understood.Reduces platelet aggregation, activates the regeneration of tissues (especially the myocardium and mucous membrane of the gastrointestinal tract).

    Pharmacokinetics:

    Metabolised in the liver with the formation of glucuronic acid and its subsequent oxidation. In a small amount, it is excreted by the kidneys.

    Indications:

    Riboxin is used in the complex treatment of myocardial infarction, ischemic heart disease, heart rhythm disorders caused by the use of cardiac glycosides, myocardial dystrophy after the infectious diseases.

    The use of the drug is also indicated for liver diseases (hepatitis, cirrhosis, fatty liver disease), for the treatment of urocoppororphyria.

    In addition, riboksin is used in operations on an isolated kidney as a means of pharmacological protection, when the blood circulation of the operated organ is temporarily turned off.

    Contraindications:

    Hypersensitivity to the drug, gout, hyperuricemia, pregnancy, lactation, age under 18 years (efficacy and safety not established).

    Dosing and Administration:

    Riboxin is administered intravenously.

    Intravenous (slow, jet or drip - 40-60 cap / min): begin with the introduction of 200 mg (10 ml of 2% solution) once a day, then, with good tolerability, increase the dose to 400 mg (20 ml of 2% solution ) 1-2 times a day.

    Duration of treatment is 10-15 days.

    In acute disorders of rhythm and conductivity, a jet injection of a single dose of 200-400 mg is permissible.

    For pharmacological protection of the kidneys subjected to ischemia, intravenously injected, in a single dose of 1.2 g (60 ml 2% solution) for 5-15 minutes before clamping the renal artery, and then another 800 mg (40 ml of 2% solution) immediately after the restoration of blood circulation.

    For intravenous drip 2% the solution is diluted in a 5% solution of dextrose or 0.9% solution of sodium chloride (up to 250 ml).

    Side effects:

    Allergic reactions: skin itching, skin hyperemia (drug should be discarded).

    Rarely: increased concentration of uric acid in the blood, exacerbation of gout (with prolonged use).

    Interaction:

    When combined with cardiac glycosides, the drug can prevent the occurrence of arrhythmias, enhance the positive inotropic effect.

    Special instructions:

    In case of renal insufficiency, the use of the drug is possible only in the case,if, in the opinion of the doctor, the expected positive effect prevails over the possible risk from the use.

    During treatment, the level of urea is monitored.

    Form release / dosage:

    Solution for intravenous administration, 20 mg / ml.

    Packaging:

    By 5 or 10 ml into ampoules-neutral glass.

    10 ampoules in a contour squamous package.

    1 contour pack with instructions for use in a pack of cardboard.

    Storage conditions:

    In the dark place at a temperature of 15 to 30 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-010330/08
    Date of registration:22.12.2008
    The owner of the registration certificate:VIAL, LLC VIAL, LLC Russia
    Manufacturer: & nbsp
    Representation: & nbspVIAL, LLCVIAL, LLC
    Information update date: & nbsp23.10.2015
    Illustrated instructions
      Instructions
      Up